Jeremy Parsons, MD
Family Medicine · Pikeville, KYNPI 1811180409
Payments from drug & device makers
Across 348 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$849
- Novo Nordisk$780
- Lilly USA, LLC$453
- AstraZeneca$423
- GSK$397
- Bayer$328
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,22699%
- Education$331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $849 |
| Novo Nordisk | 64 | $780 |
| Lilly USA, LLC | 36 | $453 |
| AstraZeneca(2 entities) | 24 | $423 |
| GSK | 28 | $397 |
| Bayer | 23 | $328 |
| Amgen | 16 | $311 |
| Merck | 21 | $268 |
| Pfizer | 19 | $248 |
| Boehringer Ingelheim | 10 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $122 |
| Daiichi Sankyo Inc. | 7 | $106 |
| Novartis | 6 | $97 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $89 |
| Johnson & Johnson | 6 | $89 |
| Supernus Pharmaceuticals, Inc. | 5 | $70 |
| Teva Pharmaceuticals USA, Inc. | 5 | $65 |
| Sanofi-aventis U.S. LLC | 4 | $55 |
| Dexcom, Inc. | 2 | $49 |
| Astellas Pharma US Inc | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| Genentech USA, Inc. | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Circassia Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Abbott | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Smith+Nephew | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,259 in reported general payments places this provider in the 85th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 227 | $223,825 |
| FarxigaDapagliflozin Propanediol | 186 | $162,584 |
| LinzessLinaclotide | 172 | $125,513 |
| TrulicityDulaglutide | 107 | $105,334 |
| XareltoRivaroxaban | 86 | $85,295 |
| MounjaroTirzepatide | 83 | $83,303 |
| EliquisApixaban | 106 | $74,198 |
| JardianceEmpagliflozin | 71 | $62,517 |
| Dupixent SyringeDupilumab | 12 | $42,900 |
| XifaxanRifaximin | 11 | $35,410 |
| EntrestoSacubitril/Valsartan | 41 | $31,786 |
| Oxtellar XrOxcarbazepine | 13 | $26,182 |
| Victoza 3-PakLiraglutide | 22 | $24,562 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $22,821 |
| RybelsusSemaglutide | 20 | $18,611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $780 | $242,436247 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $453 | $188,637190 claims |
| AstraZenecaFarxiga, Symbicort | $423 | $175,193222 claims |
| AbbVieLinzess | $849 | $125,513172 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Jentadueto | $145 | $98,688134 claims |
| Johnson & JohnsonXarelto | $89 | $85,29586 claims |
| PfizerEliquis | $248 | $74,198106 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $89 | $35,41011 claims |
| NovartisEntresto | $97 | $31,78641 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $397 | $29,45339 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $70 | $26,18213 claims |
| Astellas Pharma US IncMyrbetriq | $41 | $11,71825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Pikeville
- Suzanne FordPikeville$19K
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.